1. Home
  2. EDIT
  3. EDIT News

Latest Editas Medicine Inc. (EDIT) News on November 26, 2025

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
EDIT

Zacks

5 days ago

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know

Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies
EDIT

Business Wire

6 days ago

Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies

Top 3 Genomics Stocks to Consider for Your Portfolio
EDIT

Zacks

8 days ago

Top 3 Genomics Stocks to Consider for Your Portfolio

EDIT

MT Newswires

13 days ago

Chardan Capital Upgrades Editas Medicine to Buy From Neutral, Price Target is $3.50

Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates
EDIT

Simply Wall St.

13 days ago

Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates

Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
EDIT

Zacks

14 days ago

Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y

Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates
EDIT

Zacks

16 days ago

Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates

EDIT

Associated Press Finance

16 days ago

Editas: Q3 Earnings Snapshot

Editas Medicine Announces Third Quarter 2025 Results and Business Updates
EDIT

GlobeNewswire

16 days ago

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates
EDIT

Zacks

19 days ago

Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates
EDIT

Zacks

19 days ago

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
EDIT

GlobeNewswire

23 days ago

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
EDIT

Zacks

a month ago

Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
EDIT

GlobeNewswire

2 months ago

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Scientific Equipment Goes to Auction in Tiger Group and EquipNet Sale on Oct. 16
EDIT

PR Newswire

2 months ago

Scientific Equipment Goes to Auction in Tiger Group and EquipNet Sale on Oct. 16

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
EDIT

GlobeNewswire

2 months ago

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

EDIT

MT Newswires

2 months ago

KalVista Pharmaceuticals Names Bilal Arif as COO, Linea Aspesi as Chief People Officer

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?
EDIT

Motley Fool

5 months ago

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

2 Beaten-Down Stocks to Avoid
EDIT

Motley Fool

5 months ago

2 Beaten-Down Stocks to Avoid

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
EDIT

Motley Fool

5 months ago

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
EDIT

GlobeNewswire

5 months ago

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
EDIT

Zacks

5 months ago

Why Is Editas (EDIT) Up 40% Since Last Earnings Report?

1 Stock Down 97% That Could Double, According to Wall Street
EDIT

Motley Fool

6 months ago

1 Stock Down 97% That Could Double, According to Wall Street

A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory
EDIT

Pharma Voice

6 months ago

A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
EDIT

GlobeNewswire

6 months ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

Editas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
EDIT

Simply Wall St.

6 months ago

Editas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
EDIT

GlobeNewswire

6 months ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
EDIT

Zacks

6 months ago

Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
EDIT

Zacks

6 months ago

Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
EDIT

GlobeNewswire

6 months ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
EDIT

Zacks

6 months ago

Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

EDIT

Associated Press Finance

6 months ago

Editas: Q1 Earnings Snapshot

Editas Medicine Announces First Quarter 2025 Results and Business Updates
EDIT

GlobeNewswire

6 months ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
EDIT

GlobeNewswire

6 months ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock?
EDIT

Zacks

6 months ago

Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock?

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
EDIT

GlobeNewswire

7 months ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
EDIT

GlobeNewswire

7 months ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

EDIT

MT Newswires

7 months ago

HC Wainwright Initiates Coverage on Editas Medicine With Buy Rating, $3 Price Target

Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year
EDIT

Simply Wall St.

7 months ago

Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year

Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?
EDIT

Zacks

8 months ago

Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?

AstraZeneca deepens China investment; Editas loses CFO to Dyne
EDIT

BioPharma Dive

8 months ago

AstraZeneca deepens China investment; Editas loses CFO to Dyne

EDIT

MT Newswires

8 months ago

Dyne Therapeutics Names Erick Lucera as CFO

Editas Medicine Announces Chief Financial Officer Transition
EDIT

GlobeNewswire

8 months ago

Editas Medicine Announces Chief Financial Officer Transition

Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely
EDIT

Simply Wall St.

8 months ago

Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely

Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
EDIT

Zacks

9 months ago

Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates
EDIT

Zacks

9 months ago

Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates

EDIT

Associated Press Finance

9 months ago

Editas: Q4 Earnings Snapshot

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
EDIT

GlobeNewswire

9 months ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
EDIT

GlobeNewswire

9 months ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
EDIT

Zacks

9 months ago

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Editas Medicine Outlines 2025 Strategic Priorities and Milestones
EDIT

TipRanks

10 months ago

Editas Medicine Outlines 2025 Strategic Priorities and Milestones

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
EDIT

Zacks

10 months ago

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
EDIT

GlobeNewswire

10 months ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
EDIT

Zacks

a year ago

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
EDIT

GlobeNewswire

a year ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?
EDIT

Insider Monkey

a year ago

Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce
EDIT

Zacks

a year ago

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

EDIT

MT Newswires

a year ago

JPMorgan Downgrades Editas Medicine to Underweight From Neutral

Editas Medicine price target lowered to $8 from $10 at Baird
EDIT

TipRanks

a year ago

Editas Medicine price target lowered to $8 from $10 at Baird

EDIT

Investing.com

a year ago

Brokerages downgrade gene editing company Editas to 'hold', shares slump 23%

Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts
EDIT

GuruFocus.com

a year ago

Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts

EDIT

MT Newswires

a year ago

JonesTrading Downgrades Editas Medicine to Hold From Buy

EDIT

MT Newswires

a year ago

Stifel Downgrades Editas Medicine Hold From Buy, Adjusts Price Target to 3 From $11

EDIT

MT Newswires

a year ago

Truist Securities Downgrades Editas Medicine Hold From Buy

EDIT

MT Newswires

a year ago

RBC Cuts Price Target on Editas Medicine to $4 From $5, Keeps Sector Perform, Speculative Risk

EDIT

MT Newswires

a year ago

Truist Downgrades Editas Medicine to Hold From Buy, Removes $8 Price Target

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
EDIT

Benzinga

a year ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

EDIT

MT Newswires

a year ago

Editas Medicine Focuses on In Vivo Gene-Editing Medicines, Ends Reni-Cel Development to Cut Costs

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
EDIT

GlobeNewswire

a year ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Editas to lay off staff after search for sickle cell partner comes up empty
EDIT

BioPharma Dive

a year ago

Editas to lay off staff after search for sickle cell partner comes up empty

EDIT

MT Newswires

a year ago

Wells Fargo Downgrades Editas Medicine to Equal Weight From Overweight, Cuts Price Target to $4 From $7

Editas Stock Rises on Updated Data From SCD Study of Reni-Cel
EDIT

Zacks

a year ago

Editas Stock Rises on Updated Data From SCD Study of Reni-Cel

EDIT

MT Newswires

a year ago

Editas Medicine Shares Jump as Potential Gene Therapy for Sickle Cell Disease Found to Be 'Well-Tolerated'

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
EDIT

GlobeNewswire

a year ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?
EDIT

Zacks

a year ago

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?

Editas Medicine downgraded to Underperform from Buy at BofA
EDIT

TipRanks

a year ago

Editas Medicine downgraded to Underperform from Buy at BofA

EDIT

MT Newswires

a year ago

BofA Securities Downgrades Editas Medicine to Underperform

Editas Medicine to Participate in Upcoming Investor Conferences
EDIT

GlobeNewswire

a year ago

Editas Medicine to Participate in Upcoming Investor Conferences

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19%
EDIT

Simply Wall St.

a year ago

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19%

Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty
EDIT

GuruFocus.com

a year ago

Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y
EDIT

Zacks

a year ago

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
EDIT

Zacks

a year ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Editas Medicine Third Quarter 2024 Earnings: Misses Expectations
EDIT

Simply Wall St.

a year ago

Editas Medicine Third Quarter 2024 Earnings: Misses Expectations

EDIT

MT Newswires

a year ago

Raymond James Downgrades Editas Medicine to Market Perform From Outperform

EDIT

MT Newswires

a year ago

Truist Securities Adjusts Editas Medicine's Price Target to $8 From $12, Keeps Buy Rating

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
EDIT

Zacks

a year ago

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

EDIT

Associated Press Finance

a year ago

Editas: Q3 Earnings Snapshot

Editas Medicine Announces Third Quarter 2024 Results and Business Updates
EDIT

GlobeNewswire

a year ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?
EDIT

Insider Monkey

a year ago

Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?

Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for
EDIT

Zacks

a year ago

Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for

Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline
EDIT

Zacks

a year ago

Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More
EDIT

Zacks

a year ago

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down
EDIT

Zacks

a year ago

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

EDIT

MT Newswires

a year ago

Chardan Cuts Price Target on Editas Medicine to $12 From $20, Keeps Buy Rating

Editas and Genevant team up to develop gene editing therapies
EDIT

Pharmaceutical Technology

a year ago

Editas and Genevant team up to develop gene editing therapies

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies
EDIT

Zacks

a year ago

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies

EDIT

MT Newswires

a year ago

Editas Medicine Achieves Proof of Concept for In Vivo Gene Editing of Hematopoietic Stem Cells in Humanized Mice

Editas, changing course again, looks to partner lead CRISPR therapy
EDIT

BioPharma Dive

a year ago

Editas, changing course again, looks to partner lead CRISPR therapy

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
EDIT

GlobeNewswire

a year ago

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

EDIT

MT Newswires

a year ago

Editas Medicine, Genevant Partner to Develop mRNA-LNP Gene Editing Therapeutics

Share on Social Networks: